DRIO vs. MLSS, SRTS, ICAD, HYPR, LUCD, MGRM, NTRB, NSPR, GUTS, and ICCM
Should you be buying DarioHealth stock or one of its competitors? The main competitors of DarioHealth include Milestone Scientific (MLSS), Sensus Healthcare (SRTS), iCAD (ICAD), Hyperfine (HYPR), Lucid Diagnostics (LUCD), Monogram Orthopaedics (MGRM), Nutriband (NTRB), InspireMD (NSPR), Fractyl Health (GUTS), and IceCure Medical (ICCM). These companies are all part of the "medical equipment" industry.
DarioHealth vs.
Milestone Scientific (NYSE:MLSS) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations.
DarioHealth received 236 more outperform votes than Milestone Scientific when rated by MarketBeat users. Likewise, 66.85% of users gave DarioHealth an outperform vote while only 2.41% of users gave Milestone Scientific an outperform vote.
5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 24.8% of Milestone Scientific shares are held by insiders. Comparatively, 16.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Milestone Scientific has higher earnings, but lower revenue than DarioHealth. Milestone Scientific is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.
Milestone Scientific currently has a consensus price target of $1.25, suggesting a potential upside of 20.19%. DarioHealth has a consensus price target of $2.50, suggesting a potential upside of 262.32%. Given DarioHealth's higher probable upside, analysts plainly believe DarioHealth is more favorable than Milestone Scientific.
In the previous week, Milestone Scientific had 1 more articles in the media than DarioHealth. MarketBeat recorded 1 mentions for Milestone Scientific and 0 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.67 beat Milestone Scientific's score of 0.00 indicating that DarioHealth is being referred to more favorably in the news media.
Milestone Scientific has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Milestone Scientific has a net margin of -52.01% compared to DarioHealth's net margin of -205.62%. Milestone Scientific's return on equity of -60.26% beat DarioHealth's return on equity.
Summary
Milestone Scientific beats DarioHealth on 9 of the 17 factors compared between the two stocks.
Get DarioHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DarioHealth Competitors List
Related Companies and Tools
This page (NASDAQ:DRIO) was last updated on 2/22/2025 by MarketBeat.com Staff
Free DRIO Stock Alerts